Glp3-Rt Side Effects: A Review of Adverse Events Reported in Published Research
· 8 min read
Quick answer: In the published Phase 2 trial of Glp3-Rt, the most common adverse events were gastrointestinal; they were dose-related, they were mostly mild to moderate in severity, and they were partly reduced by starting at a lower dose. The trial also reported dose-dependent increases in heart rate that peaked around 24 weeks and declined afterward. Everything below is a summary of what the human clinical literature reported. It is not a description of what any research compound does, and Velora supplies Glp3-Rt strictly for in-vitro research.
Research use only: what this article is, and what it isn’t
This is the most important framing in the article, so it comes first. This piece reviews the adverse-event profile that Eli Lilly reported in its published clinical trials of Glp3-Rt. Those trials were conducted in human participants under regulated clinical conditions by the drug’s developer. The adverse events described here belong to that clinical research context, and to that context only.
Glp3-Rt is an investigational compound. It is not approved by the U.S. Food and Drug Administration, the European Medicines Agency, or any other regulator for any indication. The Glp3-Rt research compound that Velora Research supplies as GLP-3 RT is sold strictly for laboratory research use, not for human consumption, veterinary use, or in vivo use in any species. Nothing in this article implies that Velora’s product produces these or any other effects in a person. The molecule studied in Lilly’s human trials and the research-grade material sold for in-vitro work are used in completely different settings, and the adverse-event data cannot be transferred from one to the other as guidance.
This article is not medical advice, not a safety guide for any human use, and not a dosing document. It is a literature summary provided for scientific reference. Researchers are responsible for compliance with all applicable law, including the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 331, § 355, § 360bbb-3), and institutional review requirements.
Where the data comes from
The majority of reliable and publicly known information about Glp3-Rt adverse-event profile comes from a landmark study: the Phase 2, double-blind, randomized, placebo-controlled obesity trial published in The New England Journal of Medicine in 2023 (Jastreboff et al., NEJM, 2023; ClinicalTrials.gov number NCT04881760). That trial enrolled 338 adults and ran for 48 weeks, and because it was designed specifically to characterize Glp3-Rt dose-response relationship for side effects, safety, and efficacy, it is the anchor for any honest discussion of the compound’s tolerability.
Two things about that provenance are worth stating plainly. First, this is human clinical trial data generated by the manufacturer, not preclinical or in-vitro data. Second, the compound remains investigational, so the safety picture is still being filled in by the ongoing Phase 3 program. Treat what follows as the state of the published evidence in mid-2026, not as a final safety profile.
The gastrointestinal signal
The headline tolerability finding is gastrointestinal. In the Phase 2 trial, the authors reported that the most common adverse events in the Glp3-Rt groups were gastrointestinal; these events were dose-related, they were mostly mild to moderate in severity, and they were partially mitigated by using a lower starting dose (a 2 mg initial dose rather than 4 mg) before escalating.
This pattern will look familiar to anyone who follows the incretin field. Gastrointestinal effects are the characteristic tolerability signal of agents that act on the glucagon-like peptide-1 (GLP-1) receptor, and the same broad class of symptoms, typically nausea, vomiting, diarrhea, and constipation, recurs across GLP-1 and dual GLP-1/GIP agonists. Glp3-Rt adds a third receptor to that pharmacology, which is worth understanding mechanistically rather than treating the GI profile as a surprise.
The “dose-related” and “partially mitigated with a lower starting dose” details are the scientifically interesting part. A dose-response relationship in adverse events, paired with the observation that gradual escalation reduces them, is consistent with the tolerance-building approach used across the incretin class. It is also why the trial used several different starting-dose arms rather than a single fixed regimen.
The cardiovascular observation
The second reported signal was cardiovascular, and it was specific. The trial described dose-dependent increases in heart rate that peaked at 24 weeks and then declined thereafter (Jastreboff et al., NEJM, 2023). Two features of that sentence matter: the increase scaled with dose, and it was not monotonic over time. It rose, peaked mid-trial, and came back down.
Heart-rate effects are an established area of attention for incretin-based agents generally, and the fact that the Phase 2 trial characterized the time course rather than just noting the effect is exactly the kind of detail the ongoing cardiovascular-outcomes work in the Phase 3 program is designed to resolve. This remains an active area of investigation, and it should be treated as such.
Why a triple agonist has this profile
Glp3-Rt is an agonist at three receptors at once: GLP-1, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. Mapping the reported tolerability signals onto that pharmacology is a useful way to understand them, as long as the mapping is presented as mechanistic context rather than a claim about any individual’s experience.
| Receptor target | Established role in the incretin/metabolic axis | Tolerability domain most often discussed |
|---|---|---|
| GLP-1 receptor | Glucose-dependent insulin secretion; delayed gastric emptying | Gastrointestinal (nausea, GI upset) |
| GIP receptor | Incretin signaling; adipose and metabolic effects | Generally well tolerated in combination |
| Glucagon receptor | Energy expenditure; hepatic lipid mobilization | Metabolic and cardiovascular parameters, including heart rate |
This table is mechanistic context drawn from the pharmacology of the receptor class. It is not a description of guaranteed effects, and it is not a dosing or administration guide. The point is simply that a compound engaging three metabolic receptors may have a tolerability profile influenced by all three, which is why the published trial tracked both gastrointestinal and cardiovascular signals.
What the ongoing research still has to answer
The Phase 2 trial was designed to characterize dose-response, not to be the final word on safety. Several questions are explicitly still open. The cardiovascular-outcomes question is being addressed in the broader Phase 3 TRIUMPH program. A head-to-head trial against tirzepatide, TRIUMPH-5, is active and is designed to provide the first randomized head-to-head comparison between Glp3-Rt and an approved dual agonist. And the liver-focused research, including a Phase 2a trial in metabolic dysfunction-associated steatotic liver disease (Sanyal et al., Nature Medicine, 2024), continues to expand the picture in specific patient populations.
The honest summary is that the gastrointestinal and heart-rate signals are the well-characterized parts of the profile, and the long-term and comparative safety questions are still being answered. On an investigational compound, saying so is not a hedge. It is the accurate description of where the evidence stands.
A note on research material versus clinical data
Here is the distinction that this whole article rests on. The adverse events above were observed in people, in Lilly’s regulated clinical trials, at defined therapeutic doses. Velora’s GLP-3 RT is a research-grade Glp3-Rt compound supplied for in-vitro, preclinical laboratory work only. The two things share a molecule, but they do not share a use case, and the human tolerability data does not describe or predict anything about the research compound in a laboratory setting.
“I want to be precise about what a safety review like this is and is not. It is a summary of what the manufacturer reported in the published human trials. It is not a claim about a research compound, and it is certainly not guidance for any person. When I review a piece like this, the line I care about most is the one between clinical trial data and research material. Those are two separate worlds, and the writing has to keep them separate.”
Clark Jones, PhD, Velora Research
Velora Research supplies GLP-3 RT, its Glp3-Rt research compound, with a batch-specific third-party Certificate of Analysis confirming identity by mass spectrometry and purity by HPLC. The same release protocol applies across the research peptide catalog, and the quality and testing process is documented end to end. For researchers who cite the published Glp3-Rt literature in their own work, using a compound with verifiable batch documentation is what keeps a methods section defensible.
Frequently asked questions
What are the most common Glp3-Rt side effects reported in research?
In the published Phase 2 trial, the most common adverse events in the Glp3-Rt groups were gastrointestinal. They were dose-related, mostly mild to moderate in severity, and partially reduced by using a lower starting dose before escalation. These are findings from a human clinical trial, not effects attributed to any research compound.
Did the trial report any cardiovascular effects?
Yes. The Phase 2 trial reported dose-dependent increases in heart rate that peaked at 24 weeks and declined thereafter. Longer-term cardiovascular questions are being addressed in the ongoing Phase 3 program.
Is Glp3-Rt FDA-approved?
No. Glp3-Rt is an investigational compound and is not approved by the FDA or any other regulator for any indication. The first Phase 2 readout was published in 2023, and the Phase 3 program is ongoing.
Do these side effects apply to Velora’s GLP-3 RT?
No. The adverse events described here were observed in human participants in Eli Lilly’s clinical trials. Velora’s GLP-3 RT is a research-grade compound sold strictly for in-vitro, preclinical laboratory use only. The clinical trial data does not describe or transfer to the research compound in a laboratory setting.
Why are gastrointestinal adverse events observed with Glp3-Rt in clinical trials? Gastrointestinal effects are the characteristic tolerability signal of agents acting on the GLP-1 receptor, and Glp3-Rt is a GLP-1, GIP, and glucagon receptor agonist. The published trial reported that these effects were dose-related and were reduced by gradual dose escalation.
Sources and further reading
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Glp3-Rt for Obesity – A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526. PubMed
- Sanyal AJ, et al. Triple hormone receptor agonist Glp3-Rt for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024. Full text
- ClinicalTrials.gov, NCT06662383, TRIUMPH-5 (Glp3-Rt vs tirzepatide head-to-head). Trial page
This article is provided for laboratory and scientific reference. Glp3-Rt is an investigational compound, not an approved drug. The adverse events summarized here were reported in Eli Lilly’s published human clinical trials and belong to that clinical research context only. Products sold by Velora Research are for in-vitro research use only and are not intended for human or veterinary use, and no adverse event described here is attributed to Velora’s research compound. Researchers are responsible for compliance with applicable laws and institutional protocols.